《公司业绩》神威药业(02877.HK)全年纯利5.03亿元人币跌0.5% 末期息连特别息共派21分人币
神威药业(02877.HK)公布截至去年12月底止全年业绩,营业额27.06亿元人民币(下同),按年升5.3%。纯利5.03亿元,按年跌0.5%;每股盈利64分。派息共21分,包括末期息12分及特别息9分。
期内,注射液销售额按年下跌8.8%至12.26亿元;软胶囊升13.9%至4.42亿元;中药配方颗粒升60%至5.02亿元。
於去年,毛利率上升0.2个百分点至73.2%。
集团指,自新冠病毒疫情爆发以来,一直未有间断地生产药物,今年首两个月的总销售额按年上升8.7%。(ek/a) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.